FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Survival Data
Fact checked by NewsPlainVerified by NewsPlain: confirmed by at least two named sources
Brief
Summit Therapeutics said Nov. 15 that it had received a complete response letter from the FDA, meaning its request to sell ivonescimab cannot be approved…
Keep reading with NewsPlain Premium
Get the full brief, the full story, what's confirmed, what's still unclear, why it matters, and every source.
4 confirmed facts, 1 open question and 2 sources behind this story.